Tadalafil Tablet, Film Coated
Product Images NDC 50090-7390

Product Visual Gallery

This gallery contains 9 technical images submitted to the FDA as part of the official labeling for Tadalafil (NDC 50090-7390). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by A-s Medication Solutions, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Label Image (Lbl500907390)

Label for Tadalafil 5 mg film-coated tablets from A-S Medication Solutions. The label states the product contains 30 tablets, with storage recommended at 68-77 degrees Fahrenheit. It includes dosage information and distributor details, listing the product as an oral prescription drug.*

FDA Label Image

Spl-tadalafil-figure-1 (Spl Tadalafil Figure 1)

Four line graphs displaying the difference in blood pressure measurements between Tadalafil and placebo over time (0 to 96 hours). The charts show standing systolic BP, standing diastolic BP, supine systolic BP, and supine diastolic BP with difference values on the y-axis (mmHg) and time on the x-axis (hours), including error bars.*

FDA Label Image

Spl-tadalafil-figure-2 (Spl Tadalafil Figure 2)

This image contains two line graphs showing changes in systolic blood pressure over 24 hours post-dose. The top graph represents standing systolic blood pressure, and the bottom graph represents supine systolic blood pressure. Two treatments are compared: Tadalafil 20 mg with doxazosin 8 mg, and placebo with doxazosin 8 mg, with blood pressure values plotted against time in hours.*

FDA Label Image

Spl-tadalafil-figure-3 (Spl Tadalafil Figure 3)

A line graph depicting changes in systolic blood pressure (mmHg) over 12 hours after administration of tadalafil or placebo, combined with 8 mg doxazosin. The x-axis shows time after drug administration, and the y-axis shows systolic BP changes. Four series compare 20 mg tadalafil and placebo given at 08:00 or 20:00 alongside doxazosin at 08:00.*

FDA Label Image

Spl-tadalafil-figure-4 (Spl Tadalafil Figure 4)

A line graph depicting plasma tadalafil concentration (µg/L) over time (hours) for three dosing regimens: single 20-mg tadalafil dose, single 5-mg tadalafil dose, and once-daily 5-mg tadalafil following 5 consecutive days of administration. The graph shows concentration levels peaking early and then declining over a 120-hour period with error bars indicating variability.*

FDA Label Image

Spl-tadalafil-figure-5 (Spl Tadalafil Figure 5)

Line graph depicting the change from baseline in IPSS total score over 12 weeks comparing Tadalafil 5 mg to placebo. The x-axis shows treatment duration in weeks, and the y-axis shows change in score. Tadalafil 5 mg demonstrates a larger decrease in score over time compared to placebo, with statistically significant difference noted at 12 weeks (p<0.01).*

FDA Label Image

Spl-tadalafil-figure-6 (Spl Tadalafil Figure 6)

Line graph comparing change from baseline in IPSS total score over 12 weeks of treatment with Tadalafil 5 mg versus placebo. The x-axis represents duration of treatment in weeks, and the y-axis shows change from baseline in IPSS scores, with Tadalafil showing greater reduction than placebo over time.*

FDA Label Image

Spl-tadalafil-figure-8 (Spl Tadalafil Figure 8)

A line graph showing change from baseline in IPSS total score over a 12-week treatment duration, comparing Tadalafil 5 mg and placebo. The graph illustrates greater improvement (decrease in score) with Tadalafil 5 mg over time compared to placebo, with data points at 0, 2, 4, 8, and 12 weeks. Tadalafil is represented by a solid line with circles, and placebo by a dashed line with triangles.*

FDA Label Image

Spl-tadalafil-structure (Spl Tadalafil Structure)

Chemical structure of tadalafil, showing its molecular framework including indole and lactam rings, methylated nitrogen, and a methylenedioxyphenyl group.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.